Screening for the Next-Generation T Cell Therapies

Jun Guo; Chenqi Xu

doi:10.1016/j.ccell.2020.04.009

Screening for the Next-Generation T Cell Therapies

Cancer Cell. 2020 May 11;37(5):627-629. doi: 10.1016/j.ccell.2020.04.009.

Authors

Jun Guo¹, Chenqi Xu²

Affiliations

¹ State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China.
² State Key Laboratory of Molecular Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China; School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China. Electronic address: cqxu@sibcb.ac.cn.

PMID: 32396857
DOI: 10.1016/j.ccell.2020.04.009

Abstract

In a recently published Cell paper, Roth et al. report a CRISPR-based platform for developing T cell therapies that strategically combine a tumor-specific TCR with novel protein factors that potentiate antitumor function.

Publication types

Comment

MeSH terms

Clustered Regularly Interspaced Short Palindromic Repeats / genetics
Humans
Immunotherapy*
Neoplasms* / genetics
Neoplasms* / therapy
T-Lymphocytes